Avandia Bigger Heart Risk Than Competitor: Study
GlaxoSmithKline PLC's popular diabetes drug Avandia may pose a greater risk of death and heart failure than Takeda Pharmaceutical Co. Ltd.'s competing drug Actos, according to a recent study....To view the full article, register now.
Already a subscriber? Click here to view full article